Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

KPTI earnings call for the period ending December 31, 2023.

KPTI : 1.1700 (-8.59%)
Karyopharm Therapeutics: Q4 Earnings Snapshot

Karyopharm Therapeutics: Q4 Earnings Snapshot

KPTI : 1.1700 (-8.59%)
Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript

KPTI earnings call for the period ending September 30, 2023.

KPTI : 1.1700 (-8.59%)
Karyopharm Therapeutics: Q3 Earnings Snapshot

Karyopharm Therapeutics: Q3 Earnings Snapshot

KPTI : 1.1700 (-8.59%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

KPTI : 1.1700 (-8.59%)
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

KPTI : 1.1700 (-8.59%)
Karyopharm to Participate at Upcoming Investor Conferences

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

KPTI : 1.1700 (-8.59%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

KPTI : 1.1700 (-8.59%)
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

KPTI : 1.1700 (-8.59%)
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China

- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and...

KPTI : 1.1700 (-8.59%)

Barchart Exclusives

Dividend Newcomers: Discover 3 Companies Starting To Share the Wealth
Discover the potential of newly initiated dividends—start building your wealth with tomorrow's top dividend payers today! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar